Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

恢复期血清和疫苗血清对 SARS-CoV-2 B.1.1.7 变体的中和作用降低

阅读:10
作者:Piyada Supasa, Daming Zhou, Wanwisa Dejnirattisai, Chang Liu, Alexander J Mentzer, Helen M Ginn, Yuguang Zhao, Helen M E Duyvesteyn, Rungtiwa Nutalai, Aekkachai Tuekprakhon, Beibei Wang, Guido C Paesen, Jose Slon-Campos, César López-Camacho, Bassam Hallis, Naomi Coombes, Kevin R Bewley, Sue Charlton

Abstract

SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in the ACE2 interacting surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterized monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light-chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。